Annexon, Inc. (NASDAQ:ANNX) Director Purchases $10,122.90 in Stock

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William H. Carson purchased 4,115 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were acquired at an average cost of $2.46 per share, with a total value of $10,122.90. Following the completion of the purchase, the director directly owned 29,715 shares in the company, valued at approximately $73,098.90. This represents a 16.07% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Annexon Price Performance

NASDAQ ANNX traded up $0.15 on Friday, hitting $2.96. 1,884,073 shares of the stock were exchanged, compared to its average volume of 1,455,587. The business's fifty day moving average is $2.20 and its 200 day moving average is $2.85. Annexon, Inc. has a 52 week low of $1.29 and a 52 week high of $7.85. The company has a market capitalization of $324.19 million, a PE ratio of -2.50 and a beta of 1.30.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Needham & Company LLC decreased their price objective on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright decreased their price target on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th.

Institutional Trading of Annexon

Hedge funds have recently made changes to their positions in the business. Alpine Global Management LLC acquired a new position in shares of Annexon during the 1st quarter worth approximately $49,000. Forefront Analytics LLC boosted its position in Annexon by 74.0% during the first quarter. Forefront Analytics LLC now owns 28,591 shares of the company's stock worth $55,000 after purchasing an additional 12,158 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Annexon in the fourth quarter valued at $59,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Annexon by 164.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company's stock valued at $66,000 after purchasing an additional 21,143 shares during the last quarter. Finally, Hsbc Holdings PLC raised its position in shares of Annexon by 19.9% in the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company's stock valued at $73,000 after purchasing an additional 6,136 shares during the period.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.